P-1298. A Comparison of Daptomycin and Linezolid in Treating Intraabdominal Infections Complicated by VRE Bacteremia

Abstract Background Vancomycin-resistant Enterococci (VRE) are pathogenic in intraabdominal infections (IAIs). While daptomycin (8–12 mg/kg) is effective for VRE bloodstream infections (BSIs), evidence supporting its use in VRE-IAIs remains limited. This study aims to evaluate the clinical efficacy of daptomycin versus linezolid in treating VRE-IAIs with BSI.Table 1The baseline characteristics of the patients in the daptomycin group and the linezolid group.Figure 1The mortality rate of patients with (a) BTI without peritonitis and liver abscesses (n=96) and with (b) peritonitis and intraabdominal abscesses (n=88), separated by the usage of linezolid, high-dose daptomycin, and low-dose daptomycin. Methods We conducted a multicenter observational study. From April 2010 to October 2024, VRE-BSI patients with IAIs as the infection source treated with daptomycin or linezolid were included. The primary outcome was the 28-day in-hospital mortality. Figure 2. The Kaplan–Meier curve of patients received linezolid, high-dose daptomycin (≥11 mg/kg), and low-dose daptomycin (